• Zielgruppen
  • Suche

The Hannover School for Biomolecular Drug Research – HSBDR –

assembles partners from Leibniz Universität Hannover (LUH), Hannover Medical School (MHH), TwinCore, Helmholtz Centre for Infection Research (HZI) and associated institutions including the Helmholtz Institute for Pharmaceutical Research, Saarland (HIPS), the Technical University Braunschweig and the University Hospital Tübingen to provide ideal and high profile research and teaching conditions for doctoral studies in the area of drug research which is located at the interface of chemistry, biology and medicine.

The HSBDR consists of 15 PhD students financed by the program of the state of Lower Saxony and 15 students financed by other funding agencies (DFG, BMBF etc.). On the long run the HSBDR plans to incorporate all PhD students at the LUH working on biomolecular drug research into this Graduate School. Therefore, the HSBDR aims at 75 PhD-Students in total on the long-term perspective.

The participating investigators and institutions of the HSBDR provide an educational background for the biomolecular drug research aimed at turning natural products into lead structures and clinical candidates. The goal is to discover new mechanisms of action and to further established drug leads for medical application in the fields of infection and cancer research.

The institutional basis for the HSBDR is the Centre of Biomolecular Drug Research (BMWZ) which was established as an interdisciplinary research centre at the Leibniz Universität Hannover. It houses research groups working in the fields of chemistry, biology and medicine. Involved institutions are the Helmholtz-Centre for Infection Research (HZI) in Braunschweig, Hannover Medical School (MHH), Technical University of Braunschweig and Twincore in Hannover. These partners are part of the Translational Alliance in Lower Saxony (TrAiN) working on establishing an innovative academic approach towards drug research. However, these efforts are only devoted to research and not to education and qualification.

Major research areas at the BMWZ and the HSBDR are:

  • Discovery and use of natural products as pre-optimized chemical leads for drug development.
  • Structure chemistry to describe interactions between drugs and their biological targets.
  • Pharmacodynamic tests of modified compounds for optimization of modes of operation.
  • Drug optimization to provide candidates for pre-clinical and clinical testing.
  • Validation of drugs for regenerative medicine in the fields of implants and stem cell research.